A mission-driven company, fully dedicated to empowering the cardiac surgeons of the future.
To company website
overview
Corcym is the sole global independent platform for surgical structural heart solutions. Since the carve-out, Gyrus has successfully repositioned the business after years of underinvestment and it is now outperforming the market as a leading independent player in cardiac surgery.
4 Foundations
Safer, more effective and longer-lasting treatments for patients with structural heart disease
Perceval valve reduces surgery time and improves outcomes
Diverse portfolio of life-saving products sold globally
Support innovation, particularly around high-growth minimally invasive / robotics techniques
Our investment journey
- Gyrus made a strategic “bet” on the evolution of cardiac surgery - from open surgery, to MICS, to robotics - offering durable solutions that complement and outperform TAVI in key segments of the population
- Smoothly executed the complex carve-out in just six months - rebuilt core functions, separated contracts, defined new processes, and implemented fit-for-purpose IT systems to establish Corcym as a fully independent structural heart platform
- Appointed a new CEO (Gyrus Operating Partner) who co-invested alongside Gyrus
- After the carve-out period, Gyrus and the management team launched a series of strategic initiatives to unlock the business’s full potential:
- Re-started the innovation engine by launching new products (Haart, Perceval Plus with Free tissue, RelyOn) and developing new capabilities (pre-op CT planning, virtual training, endoscopic/robotic academy)
- Optimized operations, centralizing global functions, simplifying manufacturing, and investing in automation and AI – appointed a new COO
- Revamped the commercial model, by introducing a new go-to-market strategy focused on priority accounts, improved service levels, and disciplined approach to pricing
Outcome
Today, Corcym is a uniquely positioned as high-quality, independent platform in a structurally growing cardiac surgery market. From flat / declining revenue growth, the company has returned to double-digit organic growth, outpacing its reference market and capitalizing on renewed global momentum in cardiac surgery
“My journey with Gyrus it is incredibly rewarding. Their deep understanding of the Medtech industry, hands-on support during the complex carve-out period, and strategic insights to help addressing sustainable growth pockets have been instrumental. Gyrus brings the right balance of operational discipline and partnership, enabling us to strengthen our market position and build for the long term”
Christian Mazzi
Corcym CEO